Ro Body ProgramvsFound Weight Loss Program

After an online visit, a licensed provider determines eligibility and can prescribe an FDA-approved GLP-1 such as the Wegovy pen, oral Wegovy, or Zepbound (with compounded options also available). These drugs target gut hormone receptors to reduce appetite and slow digestion. Ro layers on a 12-month coaching curriculum (nutrition, exercise, sleep, habits), monthly provider check-ins, messaging, and lab testing when ordered.

After an online intake and Found's MetabolicPrint assessment, a licensed clinician reviews your profile and prescribes a GLP-1 when appropriate. Cash-pay plans include compounded semaglutide or tirzepatide; branded GLP-1s can be prescribed but are billed separately. These drugs act on GLP-1 (and, for tirzepatide, GIP) receptors to reduce appetite and slow gastric emptying. The Found app delivers behavioral coaching, an AI health companion, and community support throughout.

Ro prescribes the GLP-1 medications backed by the strongest evidence: semaglutide produced roughly 15% mean weight loss in STEP 1 and tirzepatide up to about 21% in SURMOUNT-1, with the head-to-head SURMOUNT-5 trial favoring tirzepatide (~20% vs ~14%). Real-world results depend on the medication, dose, and adherence; individual results vary.

The GLP-1 actives Found uses are the same molecules studied in landmark trials, where semaglutide produced roughly 15% mean weight loss (STEP 1) and tirzepatide up to about 21% (SURMOUNT-1). However, compounded formulations are not FDA-approved and have not been individually tested for the brand-name trial endpoints, so results may differ. Individual results vary.

Expect common GI side effects (nausea, vomiting, diarrhea or constipation), most pronounced during dose escalation. Serious but rare risks include pancreatitis and gallbladder disease. Provider check-ins and labs help monitor safety. This is educational information, not medical advice.

GLP-1 medications commonly cause nausea, constipation, and diarrhea, usually most pronounced during dose increases. Serious but rare risks include pancreatitis and gallbladder disease. Because cash plans use compounded products, ask about the compounding pharmacy and ingredients. This is educational, not medical advice.

As of 2026, membership is $39 for the first month, then $149/mo monthly or as low as ~$74/mo with annual prepay. Medication is separate: oral Wegovy from ~$149/mo, Wegovy pen ~$199/mo introductory then up to $349/mo at higher doses, and Zepbound KwikPen cash-pay ~$449/mo. Drug pricing and promos change often.

As of 2026, membership is advertised 'as low as $49/mo,' with a common 3-month Kickstart at first-month-free then $129/mo for self-pay members. Compounded GLP-1 is included in cash-pay plans; branded drugs cost extra. Kickstart excludes Medicare/Medicaid/TriCare enrollees.

Eligibility is determined by a licensed provider after an online visit, generally following GLP-1 prescribing guidelines (typically BMI 30+, or 27+ with a weight-related condition). The program is offered on a cash-pay basis with multiple medication formats.

Prospective members complete an online health quiz and metabolic assessment; a licensed clinician makes the final prescribing decision based on GLP-1 eligibility guidelines (typically BMI 30+, or 27+ with a related condition). Kickstart self-pay pricing is not available to those with in-network insurance or government plans.